Although GLP-1 medications have transformed obesity treatment, there remains a significant need for rigorous data examining how these therapies affect fertility and reproductive function in this population. The RESTORE study is currently evaluating semaglutide treatment in girls and women with PMOS and obesity, with the overarching goal of determining whether weight loss and metabolic improvements can restore ovulation and improve reproductive outcomes
The FDA has stated that it is not part of an FDA-approved drug and has not been established as safe and effective for any condition
Polyethylene glycol (PEG 3350) is considered safe for daily use and is the most commonly recommended first-line option by GI specialists
The observed weight loss was similar in magnitude to that reported with higher doses of oral semaglutide and with the approved subcutaneous formulation
Its currently being tested in large phase 3 clinical trials, expected to run throughout 2026, These studies are designed to confirm how well the drug works, how safe it is, and whether the promising results seen in smaller phase 2 trials can be replicated in larger groups
You should generally not use GLP-1 medications if: You have a personal history of Medullary Thyroid Cancer